Molecular and Immunologic Signatures are Related to Clinical Benefit from Treatment with Vocimagene Amiretrorepvec (Toca 511) and 5-Fluorocytosine (Toca FC) in Patients with GliomaWilliam P. Accomando, Derek Ostertag, Harry E. Gruber et al.|Clinical Cancer Research|2020Cited by 29
Supplementary Material from Molecular and Immunologic Signatures are Related to Clinical Benefit from Treatment with Vocimagene Amiretrorepvec (Toca 511) and 5-Fluorocytosine (Toca FC) in Patients with GliomaWilliam P. Accomando, Derek Ostertag, Aliz R. Rao et al.|Unknown|2023Cited by 0
Data from Molecular and Immunologic Signatures are Related to Clinical Benefit from Treatment with Vocimagene Amiretrorepvec (Toca 511) and 5-Fluorocytosine (Toca FC) in Patients with GliomaWilliam P. Accomando, Derek Ostertag, Aliz R. Rao et al.|Unknown|2023Cited by 0
Data from Molecular and Immunologic Signatures are Related to Clinical Benefit from Treatment with Vocimagene Amiretrorepvec (Toca 511) and 5-Fluorocytosine (Toca FC) in Patients with GliomaWilliam P. Accomando, Derek Ostertag, Aliz R. Rao et al.|Unknown|2023Cited by 0
Supplementary Material from Molecular and Immunologic Signatures are Related to Clinical Benefit from Treatment with Vocimagene Amiretrorepvec (Toca 511) and 5-Fluorocytosine (Toca FC) in Patients with GliomaWilliam P. Accomando, Derek Ostertag, Aliz R. Rao et al.|Unknown|2023Cited by 0